USPTO serial 88912528
SYN-NAT
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 11, 2025
- Examiner
- HAYS, CANDACE W
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with SYN-NAT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Medoncare Pharmaceutical Co., Ltd.
Changsha, Hunan, CN
Other trademarks owned by Medoncare Pharmaceutical Co., Ltd.
Medoncare Pharmaceutical Co., Ltd.
Changsha, Hunan, CN
Other trademarks owned by Medoncare Pharmaceutical Co., Ltd.
Medoncare Pharmaceutical Co., Ltd.
Changsha, Hunan, CN
Other trademarks owned by Medoncare Pharmaceutical Co., Ltd.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Timothy T. Wang
Timothy T. Wang NI, WANG & MASSAND, PLLC8140 WALNUT HILL LANE, SUITE 500DALLAS, TX 75231United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Tonics of medicines, namely, medicinal tea; Medicines for human purposes in the form of effervescent tablets, chewable tablet and chewing gum for use in preventing prostatitis, benign prostatic hyperplasia, urinary tract infection, gynecological inflammation, gastrointestinal disease; Medicines for human purposes in the form of effervescent tablets, chewable tablet and chewing gum for use in blood sugar regulation, liver protection, and as antioxidants, anti-hyperlipidemia, anti-aging, antineoplastic and antiviral agents for medical use; Medicines for human purposes, namely, medicines for the treatment of gastrointestinal disease, skin disease, cardiovascular disease, gout, asthma, nasitis, prostatic cancer, leukemia, melanoma, brain glioma, colon cancer, cervical cancer, thyroid cancer, kidney cancer, stomach cancer and lung cancer, hepatitis B, hepatitis C, AIDS and influenza, prostatitis, benign prostatic hyperplasia and gynecological inflammation, diabetes, sleep disorder and rheumatoid arthritis; Medicinal drinks; Capsules sold empty for pharmaceuticals; Pharmaceutical preparations for the treatment of gastrointestinal disease, skin disease, cardiovascular disease, gout, asthma, nasitis, prostatic cancer, leukemia, melanoma, brain glioma, colon cancer, cervical cancer, thyroid cancer, kidney cancer, stomach cancer and lung cancer, hepatitis B, hepatitis C, AIDS and influenza, prostatitis, benign prostatic hyperplasia and gynecological inflammation, diabetes, sleep disorder and rheumatoid arthritis; Chemico-pharmaceutical preparations for tumor-suppression and antiviral treatment; Troches, namely, tablets for use in tumor-suppression, as antivirals and for the treatment of chronic gastrointestinal disease; Tinctura in the nature of medicinal herb extracts; Herbs for medicinal purposes; Nutritional supplements; dietetic foods adapted for medical use, namely, dietetic drinks, dietetic crackers, dietetic sugar for medical use, dietetic sugar substitutes for medical use; Dietary and nutritional supplements; Dietary food supplements; Dietary supplemental drinks; Dietary supplements; Dietetic beverages adapted for medical use; Dietetic foods adapted for medical purposes; Dietetic foods and beverages adapted for medical use; Nutraceuticals for use as a dietary supplement; Nutritional supplements in the form of capsules, tablets, caplets, powder, syrups, gummies and gels; Sanitizing preparations for commercial use | ACTIVE | Apr 12, 2024 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Medoncare Pharmaceutical Co., Ltd.
- Other trademarks owned by Medoncare Pharmaceutical Co., Ltd.
- Other trademarks owned by Medoncare Pharmaceutical Co., Ltd.
- Other trademarks in Class 005
- Similar marks named SYN-NAT
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 11, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Mar 11, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 15, 2025 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Feb 15, 2025 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Feb 14, 2025 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Feb 14, 2025 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Dec 3, 2024 | IUAF | USE AMENDMENT FILED | — |
| Dec 3, 2024 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Jun 4, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Apr 2, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 2, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 13, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 29, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 29, 2023 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Mar 1, 2023 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Jan 17, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 1, 2022 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Mar 1, 2022 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Aug 28, 2021 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Feb 17, 2021 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Feb 17, 2021 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Feb 17, 2021 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Feb 16, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 16, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 26, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 26, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 26, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 16, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 16, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 16, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 15, 2020 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Aug 15, 2020 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Aug 15, 2020 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Aug 8, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| May 26, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 15, 2020 | NWAP | NEW APPLICATION ENTERED | — |